BC
KALA icon

Broadfin Capital’s KALA BIO KALA Stock Holding History

Broadfin Capital’s Portfolio KALA Stock Details KALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-136
Closed -$1.66M – 44
2018
Q4 		$1.66M Sell
136
-3
-2% -$52K 0.22% 46
2018
Q3 		$3.42M Sell
139
-101
-42% -$3.08M 0.5% 41
2018
Q2 		$8.22M Sell
240
-33
-12% -$1.27M 1.29% 26
2018
Q1 		$10.8M Buy
+273
New +$10.4M 1.68% 20

Other funds holding KALA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Broadfin Capital's KALA Position: Q1 2019 in Review

Broadfin Capital sold out of KALA BIO (KALA) in Q1 2019, closing a stake of 136 shares — an estimated $1.66M sold.

Broadfin Capital first reported a position in KALA in Q1 2018 and held it in 4 quarters. The position peaked at $10.8M in Q1 2018. 68 funds tracked by Wall St. Rank hold KALA as of Q1 2019.

  • Broadfin Capital reported no remaining KALA BIO position as of Q1 2019 after selling out during the quarter.
  • Broadfin Capital sold 136 KALA BIO shares in Q1 2019, an estimated $1.66M.
  • Broadfin Capital first reported a position in KALA BIO in Q1 2018 and held it in 4 quarters.
  • Broadfin Capital's KALA BIO position peaked at $10.8M in Q1 2018.
  • 68 funds tracked by Wall St. Rank held KALA BIO as of Q1 2019.

Based on Broadfin Capital's 13F filing for Q1 2019, filed 15 May 2019.